Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir in Japanese HSCT or SOT recipients with CMV infection
jRCT2021210056Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Primary endpoints: Percentage of participants who achieved confirmed clearance of plasma CMV DNA at Week 8, Number of participants with treatment-emergent adverse events and serious treatment-emergent adverse events and 7 more. Started Jan 2022; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT2021210056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210056.